Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ethionamide→

Ethionamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
536-33-4
Molecular formula
C8H10N2S
Molecular weight
166.243 g/mol
Drug class
Carbothioamide antimycobacterialsecond-line antituberculosis agent
Mechanism of action
A prodrug activated by the mycobacterial EthA enzyme. Its active metabolite inhibits InhA, a key enzyme in mycolic-acid synthesis required for the Mycobacterium tuberculosis cell wall.
Indications / reported uses
  • Treatment of drug-resistant tuberculosis as part of an appropriately selected multidrug regimen.

Sources: https://tbksp.who.int/sites/default/files/2025-06/3332%20HANDBOOK%20Module%204%20210525%20ACCESSIBLE%20ELECTRONIC.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ethionamide Environmental Risk Assessment (ERA) (the Ethionamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.